Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$27.0 million.

  • Zentalis Pharmaceuticals' Cash from Operations rose 3878.31% to -$27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$134.0 million, marking a year-over-year increase of 2197.76%. This contributed to the annual value of -$170.9 million for FY2024, which is 1778.54% up from last year.
  • Per Zentalis Pharmaceuticals' latest filing, its Cash from Operations stood at -$27.0 million for Q3 2025, which was up 3878.31% from -$34.7 million recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Cash from Operations peaked at -$27.0 million during Q3 2025, and registered a low of -$79.3 million during Q2 2023.
  • Moreover, its 4-year median value for Cash from Operations was -$39.7 million (2024), whereas its average is -$42.4 million.
  • In the last 5 years, Zentalis Pharmaceuticals' Cash from Operations crashed by 8424.48% in 2023 and then skyrocketed by 5567.46% in 2024.
  • Over the past 4 years, Zentalis Pharmaceuticals' Cash from Operations (Quarter) stood at -$37.3 million in 2022, then decreased by 8.76% to -$40.6 million in 2023, then grew by 2.21% to -$39.7 million in 2024, then soared by 32.09% to -$27.0 million in 2025.
  • Its Cash from Operations was -$27.0 million in Q3 2025, compared to -$34.7 million in Q2 2025 and -$32.6 million in Q1 2025.